AKT1 and cancer: Supporting our hypothesis, however, Gohr et al. 2017 identified that the PI3K/AKT signalling pathway is associated with cisplatin resistance [31], and that as acquired resistance to cisplatin developed the levels of p-AKT in cancer cells also increased [31].